

# Christopher D Breder

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3306382/publications.pdf>

Version: 2024-02-01

10  
papers

63  
citations

1936888

4  
h-index

1588620

8  
g-index

10  
all docs

10  
docs citations

10  
times ranked

81  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Multifaceted Perspective of Pharmaceutical Innovation: A Consideration of the Regulatory Role. Therapeutic Innovation and Regulatory Science, 2021, 55, 262-269.	0.8	0
2	Investigation of Factors Associated With Immunogenicity Labeling Updates and Characteristics of Biologics License Applications. Clinical Pharmacology and Therapeutics, 2021, 110, 1381-1388.	2.3	1
3	Correlates of time to approval and other clinical development periods. Drug Discovery Today, 2019, 24, 1871-1876.	3.2	0
4	Identification of factors associated with first-cycle drug approval rates and regulatory outcomes for new drug applications. Pharmacological Research, 2019, 139, 166-172.	3.1	3
5	Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016. Therapeutic Innovation and Regulatory Science, 2019, 53, 752-758.	0.8	5
6	Exposureâ€” and Doseâ€”response Analyses in Dose Selection and Labeling of FDA-approved Biologics. Clinical Therapeutics, 2018, 40, 95-102.e2.	1.1	14
7	A Critical Evaluation of Safety Signal Analysis Using Algorithmic Standardised MedDRA Queries. Drug Safety, 2018, 41, 1375-1385.	1.4	8
8	Whatâ€™s the Regulatory Value of a Target Product Profile?. Trends in Biotechnology, 2017, 35, 576-579.	4.9	19
9	Patterns of use and impact of standardised MedDRA query analyses on the safety evaluation and review of new drug and biologics license applications. PLoS ONE, 2017, 12, e0178104.	1.1	11
10	A Method for Retrieval of Adverse Event Terms in Clinical Trial Databases Using Standardised MedDRA Queries. Pharmaceutical Medicine, 2016, 30, 103-108.	1.0	2